Loading company…
SineuGene develops gene therapies and evaluation systems for neurological diseases.
SineuGene develops gene therapy drugs and disease models for neurological conditions, including amyotrophic lateral sclerosis, stroke, and Parkinson's disease. Founded in 2021, it is based in Beijing, China. In August 2024, it raised approximately CNY 100 million in pre-Series A+ funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in